Forest Namenda Has 10% Off-Label Use Based On Initial Launch Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The company said 70% of use was in moderate Alzehimer's cases and 20% was in severe cases. The company expects to file an sNDA for a mild-to-moderate indication by "late this summer."